Antibacterial phage, phage peptides and methods of use thereof
Inventors
da Costa Garcia, Miguel Ângelo • Sousa de São José, Carlos Jorge • Rodrigues Leandro, Clara Isabel • Marçal Da Silva, Filipa Maria Rodrigues Pardal Dias Antunes • Martins Barbosa, Ana Raquel
Assignees
Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9399049-B2
Publication Date
2016-07-26
Expiration Date
Abstract
The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.
Core Innovation
The invention relates to novel antibacterial bacteriophages and isolated phage polypeptides, including bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10. The disclosure describes purified bacteriophages defined by specific nucleic acid sequences, including a purified bacteriophage having a nucleic acid sequence of SEQ ID NO:560, and includes components such as lysins/endolysins, CHAP domains, and tail proteins.
The problem addressed is reducing the incidence of a Staphylococcus aureus infection in a subject in need thereof, including infection by methicillin-resistant Staphylococcus aureus (MRSA). The document presents an approach in which an effective amount of a pharmaceutical composition containing a purified bacteriophage and a pharmaceutically acceptable carrier is administered to treat or reduce infection incidence.
In addition to individual phages, the document describes the formation of phage cocktails and provides documented phage-to-pathogen mappings for multiple bacteria, including Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus including MRSA. The patent also links phage genome sequence identity to host range and sensitivity considerations, and presents isolated phage polypeptides as part of the antibacterial concept.
Claims Coverage
The provided independent claim content includes one core inventive feature: a treatment or reduction method for a Staphylococcus aureus infection using a pharmaceutical composition comprising a purified bacteriophage defined by nucleic acid sequence SEQ ID NO:560 and a pharmaceutically acceptable carrier.
Treatment of Staphylococcus aureus infection with SEQ ID NO:560 phage
A method of treating or reducing the incidence of a Staphylococcus aureus infection in a subject in need thereof, comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified bacteriophage having a nucleic acid sequence of SEQ ID NO:560.
The inventive concept centers on administering an effective amount of a pharmaceutical composition containing a purified bacteriophage specified by nucleic acid sequence SEQ ID NO:560 to treat or reduce the incidence of a Staphylococcus aureus infection.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treatment or reduction of the incidence of a Staphylococcus aureus infection in a subject in need thereof, including methicillin-resistant Staphylococcus aureus (MRSA).
Phage cocktails formed from multiple purified phages are documented as part of the antibacterial approach.
Diagnostic or susceptibility testing is documented, including host range and sensitivity spot tests and identification linked to genome nucleic acid sequences and associated protein sequences or SEQ IDs.
Use as disinfectants is described in the partial content summary.
Interested in licensing this patent?